Carlisle Companies
CSL
378.85
-9.06
-2.34%
Carlisle Companies
US · CSL
#1260 by market cap
Listed 1970
378.85
-9.06
-2.34%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Citi Maintains CSL LTD(CMXHF.US) With Hold Rating, Raises Target Price to $125.61Market Newswire · 2026/10/20
-
Baird Maintains Carlisle Companies(CSL.US) With Buy Rating, Raises Target Price to $410Market Newswire · 2026/10/29
-
Company notice
CSL Ltd: U.S. Section 232 Tariffs on PharmaceuticalsASX · 2026/4/7
-
Rating change
Morgan Stanley Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $140.31Market Newswire · 2026/11/4
-
Rating change
Morgan Stanley Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $140.62Market Newswire · 2026/10/23
-
Company notice
Cara Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Vifor (International) Ltd.(13.5%),CSL Limited(13.5%)SEC · 2024/10/31
-
Rating change
Morgans Downgrades CSL LTD(CMXHF.US) to Hold Rating, Raises Target Price to $145.48Market Newswire · 2026/11/5
-
Rating change
UBS Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $157.85Market Newswire · 2026/11/4
-
Rating change
Morgan Stanley Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $139.57Market Newswire · 2026/10/19
-
Oppenheimer Maintains Carlisle Companies(CSL.US) With Buy Rating, Maintains Target Price $425Market Newswire · 2026/10/21
-
Company notice
CSL Ltd: Update on U.S. Plasma Collection NetworkASX · 2026/10/8
-
Rating change
CSL Price Target Raised 24% to A$225.00/Share by UBSDow Jones · 2026/10/30
-
Oppenheimer Maintains Carlisle Companies(CSL.US) With Buy Rating, Raises Target Price to $430Market Newswire · 2026/10/30
-
Evans and Partners Downgrades CSL to Neutral, Adjusts Price Target to AU$197.24MT Newswires · 2026/11/17
-
Rating change
UBS Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $158.38Market Newswire · 2026/10/30
-
Company notice
CSL Ltd: Agreements with U.S. on Drug Prices and ManufacturingASX · 2026/9/1
-
Goldman Sachs Maintains Carlisle Companies(CSL.US) With Buy Rating, Raises Target Price to $480Market Newswire · 2026/10/29
-
Company notice
CSL Ltd: CSL prices US$1.5 billion in Corporate BondsASX · 2026/10/7
-
Rating change
CSL Price Target Raised 12% to A$210.00/Share by MorgansDow Jones · 2026/11/5
-
Rating change
CSL Price Target Raised 10% to A$178.00/Share by JefferiesDow Jones · 2026/10/30
-
Rating change
Baird Maintains Carlisle Companies(CSL.US) With Buy Rating, Cuts Target Price to $402Market Newswire · 2026/10/13
-
Rating change
D.A. Davidson Maintains Carlisle Companies(CSL.US) With Hold Rating, Raises Target Price to $410Market Newswire · 2026/8/25
-
Rating change
Goldman Sachs Maintains Carlisle Companies(CSL.US) With Buy Rating, Announces Target Price $464Market Newswire · 2026/10/12
-
Rating change
CSL Raised to Accumulate From Hold by Ord Minnett CSL.AUDow Jones · 2026/9/16
-
Rating change
RBC Capital Upgrades CSL LTD(CMXHF.US) to Buy Rating, Raises Target Price to $152.48Market Newswire · 2026/9/16
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Carlisle Companies discussion 0 comments